Junshi Bio News Today

Staff reporter CSPC Pharmaceuticals (1093) net profit for the first three quarters of the year inched up 0.6 percent year-on-year to 4.5 bi...

Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA • The…

Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s recent approval by the FDA The drug maker’s revenue fell 19% year-on-year in the first nine months of 2023, as its net loss narrowed to 1.41 billion yuan By Molly Wen

Key Takeaways: Junshi Biosciences reported dismal results in the first quarter, with operating income plunging nearly 60% and its net loss expanding by 37% Hopes of a big revenue boost from an oral Covid drug have been dashed, and the company may not recoup its investment in the short term By Molly Wen

The Chinese stock market has seen a difficult two years. Starting with harsh regulatory crackdowns in late 2020, and then followed by strict Covid-19 lockdowns that saw entire cities grind to a standstill, the result was billions of dollars wiped off the books of China’s tech giants and once-promising enterprises. However, things are headed for a change. China is attempting...

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global T-cell Lymphoma Market By Lymphoma Type...

JERSEY CITY, N.J., July 12, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global T-cell Lymphoma Market By Lymphoma Type (Peripheral

VectorBuilder announced plans to build a $500 million gene delivery manufacturing and research campus in Guangzhou.

Ask A Fund Manager: Platinum Asset Management's Dr Bianca Ogden picks 2 medical stocks still under the radar, plus 2 well-known ones to hold.